Evidence map›Paper›PMID 39987272›Full record

ArticleOncogene2025

PTEN loss drives p53 LOH and immune evasion in a novel urothelial organoid model harboring p53 missense mutations.

Akihiro Hamada, Yuki Kita, Toru Sakatani, Kenji Nakamura, Hideaki Takada, Ryosuke Ikeuchi, Shuhei Koike, Norihiko Masuda, Kaoru Murakami, Takeshi Sano and 8 more

Abstract read
In one paragraph

Article in Oncogene, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Akihiro HamadaDepartment of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Yuki KitaDepartment of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Toru SakataniDepartment of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Kenji NakamuraDepartment of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan.ORCID http://orcid.org/0000-0003-0135-7821
Hideaki TakadaDepartment of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Ryosuke IkeuchiDepartment of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Shuhei KoikeDepartment of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Norihiko MasudaDepartment of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Kaoru MurakamiDepartment of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Takeshi SanoDepartment of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Takayuki GotoDepartment of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Ryoichi SaitoDepartment of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Yuki TeramotoDepartment of Diagnostic Pathology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Masakazu FujimotoDepartment of Diagnostic Pathology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Narumi HatanoDepartment of Biomedical Data Intelligence, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Mayumi KamadaDepartment of Biomedical Data Intelligence, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Osamu OgawaDepartment of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Takashi KobayashiDepartment of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan. selecao@kuhp.kyoto-u.ac.jp.ORCID http://orcid.org/0000-0003-1069-2816

Funding

MEXT | Japan Society for the Promotion of Science (JSPS) JP19H03790, JP22H03211, JP25713055
6 · The paper itself

Abstract

Despite missense mutation accounts for over 60% of p53 alterations while homozygous deletion (HOM) for only 5% or less in advanced bladder cancer cases, most of the previously reported mouse models are deficient of p53. Accordingly, few studies have addressed the mechanisms of missense mutation occurrence and its functional advantage over HOM in bladder cancer development. Organoids derived from Krt5-expressing mouse urothelium (K5-mUrorganoid) demonstrated the crucial role of Pten loss in driving loss of wild-type allele of Trp53 (Trp53

Indexed as

Loss of HeterozygosityMutation, MissensePTEN PhosphohydrolaseTumor Suppressor Protein p53Urinary Bladder NeoplasmsUrotheliumAnimalsDisease Models, AnimalHumansMiceMice, NudeOrganoidsPTEN PhosphohydrolasePten protein, mouseTrp53 protein, mouseTumor Suppressor Protein p53

Identifiers

PMID39987272
PMCPMC12052601

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.